Ovarian cancer is a deadly malignancy with a growing therapeutic armamentarium, though
achieving sustained benefit in the clinic remains largely elusive. Through biomarker and …

Angiogenesis is one of the hallmarks of cancer and plays a crucial role in carcinogenesis
and progression of epithelial ovarian cancer. Antiangiogenic agent is the first approved …

Here we review the latest pre-clinical and clinical developments for treatment of ovarian
cancer, presented at the American Association of Cancer Research/Rivkin Center Ovarian …

Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the formation
and progression of ovarian cancer. Several well-designed phase II and III trials studied the …

Simple Summary Ovarian cancer treatment is the deadliest of gynecological cancers but the
introduction of target therapies in its therapeutic algorithm has significantly improved …

Ovarian cancer is the second most common gynaecological malignancy and the leading
cause of death from gynaecological cancer. Although in some cases treatment is initially …

Among female-specific cancers worldwide, ovarian cancer is the leading cause of death
from gynecologic malignancy in the western world. Despite radical surgery and initial high …

Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies.
Most women present with advanced disease and develop a recurrence after radical surgery …

Epithelial ovarian cancer is a leading cause of cancer-related death for women both in the
United States and worldwide, and the effectiveness of cytotoxic chemotherapy has …

Since the establishment of tumor angiogenesis as a therapeutic target, new, effective
antiangiogenic agents have been developed. Despite their demonstrable clinical benefits …